ArticleClinical neuropsychiatry2026
Determinants of Health-Related Quality of Life Among Patients with Psoriasis Vulgaris.
Article in Clinical neuropsychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: psoriasis is a chronic immune-mediated disease that significantly impacts patients' health-related quality of life (HRQOL). While effective treatments exist, the burden of psoriasis on HRQOL and the factors influencing it remain underexplored in Vietnam. To assess HRQOL and its associated factors among patients with psoriasis vulgaris in a tertiary hospital in Vietnam. Method: a cross-sectional study was conducted from March to December 2023, including 149 patients with psoriasis vulgaris. HRQOL was evaluated using the EQ-5D-5L tool, and disease severity was assessed with the Psoriasis Area and Severity Index (PASI). Data analysis included descriptive statistics, chi-square tests, and stepwise multivariate Tobit regression to identify factors associated with the EQ-5D index. Results: the mean EQ-5D index was 0.85 (SD = 0.17), with patients reporting the fewest problems in mobility (88.6% no issues) and self-care (81.2% no issues). However, pain/discomfort (68.5%) and anxiety/depression (36.2%) were significant concerns. The EQ-5D index declined with increasing PASI scores (mild: 0.87, severe: 0.68, p < 0.01). Factors negatively associated with HRQOL included older age (Coef. = -0.003, p = 0.026), severe redness (Coef. = -0.199, p = 0.001), and pain symptoms (Coef. = -0.108, p = 0.031). Male sex was independently associated with higher HRQOL (Coef. = 0.084, p = 0.015). Fraizeron treatment was positively associated with higher HRQOL (Coef. = 0.164, p = 0.048). Conclusions: psoriasis substantially impacts HRQOL, particularly through pain and emotional burden. Older age, severe redness, and pain symptoms were associated with poorer HRQOL, whereas male sex and Fraizeron treatment were associated with higher HRQOL. Comprehensive management strategies addressing both physical symptoms and psychological well-being may help improve HRQOL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.